Navigation Links
Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
Date:1/12/2009

LymphoStat-B are trademarks of Human Genome Sciences, Inc.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities, intense competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the Company will continue to face risks related to animal and human testing, to the manufacture of ABthrax and to FDA concurrence that ABthrax meets the requirements of the ABthrax contract. If the Company is unable to meet the product requirements associated with the ABthrax contract, the U.S. government will not be required to reimburse the Company for the costs incurred or to purchase any ABthrax doses. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the in
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... --  Sigma-Aldrich Corporation (NASDAQ: SIAL ) a leading ... $50,000 product donation to the Reproducibility Project: Cancer ... from recent high-impact papers in the field of cancer ... research marketplace Science Exchange , the non-profit ... eLife. The goal of the project is ...
(Date:5/6/2015)... LONDON , May 6, 2015 ... HIV maintenance therapy with dolutegravir and rilpivirine ... start of a Phase III clinical trial programme ... (Tivicay®) and rilpivirine (Edurant® [1] ) as maintenance ... III programme comprises two replicate studies evaluating 48 ...
(Date:5/5/2015)... BARCELONA, Spain , May 6, 2015 ... and aspires to lead the European market in the ... Through this alliance ECUPHAR acquires all the assets ... the new organization in the coming weeks. Being both ... not been disclosed.      (Photo: http://photos.prnewswire.com/prnh/20150506/743274 ...
Breaking Medicine Technology:Sigma-Aldrich Donates $50K in Products to the Reproducibility Project to Foster Replicable Research and Accelerate Scientific Discoveries in Cancer Biology 2Sigma-Aldrich Donates $50K in Products to the Reproducibility Project to Foster Replicable Research and Accelerate Scientific Discoveries in Cancer Biology 3ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 2ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 3ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 4ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 5ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 6ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 7ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 8ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 9ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 10ECUPHAR Enters the Spanish and Southern European Markets Through ESTEVE 2
... SOUTH SAN FRANCISCO, Calif., March 2 Hana,Biosciences ... an Independent Data Monitoring,Committee (IDMC) has completed a ... ongoing pivotal rALLy clinical trial of Marqibo(R) (vincristine,sulfate ... lymphoblastic,leukemia (ALL) in second relapse. The results ...
... (ASX: PXS, Nasdaq: PXSL ) today announced ... the U.S. Food and Drug Administration (FDA) for Aridol, ... to help in the correct diagnosis and assessment of ... was based on a pre-NDA meeting with the FDA ...
Cached Medicine Technology:Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound 2Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound 3Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound 4Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound 5Pharmaxis Announces New Drug Application Submission for Aridol(TM) 2Pharmaxis Announces New Drug Application Submission for Aridol(TM) 3
(Date:5/6/2015)... has opened press registration for TU-Automotive Detroit as the ... headlines of major publications world-wide. With 150+ speakers from ... to share their visions for the future of connected ... to go behind the scenes and hear major automakers’ ... year we’re releasing a preview of all the major ...
(Date:5/6/2015)... Water NSW (New South ... manage and distribute imagery, LiDAR, and Elevation Data within ... driest continents on earth, and the need to ensure ... erratic seasonal rainfalls has driven the development of several ... manages raw water supplies for NSW, including high quality ...
(Date:5/6/2015)... May 06, 2015 Cloud security companies ... announced a strategic partnership to help small-to-medium businesses secure ... two industry-leading companies are teaming up to transition SafeMonk ... , “We’re thrilled to welcome SafeMonk users to the ... the people behind SafeMonk, the global powerhouse SafeNet (now ...
(Date:5/6/2015)... 2015 National Physical Fitness and Sports ... within the U.S. Department of Health and Human Services ... Fitness and Sports Month. It is dedicated to ... to health. Throughout the month of May, Americans ... fit. , The HHS details the benefits of regular ...
(Date:5/6/2015)... 2015 Most people in the United States ... other care after age 65. But less than half of ... or even talking about it, reports the May 2015 ... two problems. One is losing control over the care they'll ... Dr. David Grabowski, a professor of health care policy at ...
Breaking Medicine News(10 mins):Health News:Press Registration for TU-Automotive Detroit Now Open 2Health News:Water NSW Unlocks Imagery and Elevation Data Archive Across the Enterprise using Hexagon Geospatial Solutions 2Health News:Water NSW Unlocks Imagery and Elevation Data Archive Across the Enterprise using Hexagon Geospatial Solutions 3Health News:Sookasa Grows Globally With SafeMonk Partnership 2Health News:Sookasa Grows Globally With SafeMonk Partnership 3Health News:Narconon Arrowhead Issues Guide for Physical Fitness and Sports Month 2Health News:Narconon Arrowhead Issues Guide for Physical Fitness and Sports Month 3Health News:Start Planning Now for Long-Term Care, from the May 2015 Harvard Health Letter 2
... concern over discrepancies in official data for key sectors ... called for a revamp of the national statistical system ... the administrative set up and traditional records, the (statistical) ... changing times," Manmohan Singh said in his address at ...
... the Institute Pasteur has recently shown that the tuberculosis ... fat cells. //This formidable pathogen is protected against even ... it may remain dormant for years. ,This ... possible strategies for fighting tuberculosis. Attempts to eradicate the ...
... research centre is being planned at the Pune-based ... diseases//, a general says. ,"Stem cell therapy ... will be the futuristic treatment replacing drug therapy ... diabetes, Parkinson's disease, epilepsy, multiple sclerosis, eye and ...
... San Diego biologists have shown that the chemical language ... electrical activity in the developing nervous system. The findings ... as a treatment for a wide range of brain ... the early on-line edition of the journal Proceedings of ...
... Christmas is indeed a ‘ubiquitous’ festival, as it is celebrated ... an estimated 26 million Indian homes.// The joys of the ... are seen making the most of the special bargains and ... time for the celebration. Plans are afoot in great enthusiasm ...
... director of Clarkson's Center for Air Resources Engineering ... on airborne pollution who serves on the Environmental ... also one of scores of health officials and ... the casual link between pollutants and respiratory illnesses. ...
Cached Medicine News:Health News:Manmohan Calls for Statistical Reforms in Healthcare and Education 2Health News:Tuberculosis: The Bacillus Takes Refuge in Adipose Cells 2Health News:Military College to Set Up Stem Cell Research Centre 2Health News:Electrical Activity Alters Language Used By Nerve Cells 2Health News:Electrical Activity Alters Language Used By Nerve Cells 3Health News:Come Apart and Rest Awhile – It’s Christma 2Health News:Come Apart and Rest Awhile – It’s Christma 3Health News:Research on to Find Link Between Airborne Pollutants and Respiratory Illness 2
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
... ACUSON brand, the new Antares system, ... system that provides highly upgradeable and ... workflow efficiencies, and user-friendly ergonomics. ,The ... upon the advanced workflow and diagnostic ...
Medicine Products: